Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy

We present the case of a 27-year-old woman with inadequately controlled HNF1A maturity-onset diabetes of the young (MODY) who was successfully transitioned from sulfonylurea therapy to once-weekly monotherapy with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). More than a decade...

Descripción completa

Detalles Bibliográficos
Autores principales: Fantasia, Kathryn L, Steenkamp, Devin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6846329/
https://www.ncbi.nlm.nih.gov/pubmed/31737858
http://dx.doi.org/10.1210/js.2019-00278
_version_ 1783468859868577792
author Fantasia, Kathryn L
Steenkamp, Devin W
author_facet Fantasia, Kathryn L
Steenkamp, Devin W
author_sort Fantasia, Kathryn L
collection PubMed
description We present the case of a 27-year-old woman with inadequately controlled HNF1A maturity-onset diabetes of the young (MODY) who was successfully transitioned from sulfonylurea therapy to once-weekly monotherapy with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). More than a decade from diabetes diagnosis, she has maintained optimal glycemic control without hypoglycemia for >12 months while receiving GLP-1 RA therapy alone. This case illustrates the potential for successful use of GLP-1 RA monotherapy in patients with HNF1A MODY.
format Online
Article
Text
id pubmed-6846329
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-68463292019-11-15 Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy Fantasia, Kathryn L Steenkamp, Devin W J Endocr Soc Case Report We present the case of a 27-year-old woman with inadequately controlled HNF1A maturity-onset diabetes of the young (MODY) who was successfully transitioned from sulfonylurea therapy to once-weekly monotherapy with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). More than a decade from diabetes diagnosis, she has maintained optimal glycemic control without hypoglycemia for >12 months while receiving GLP-1 RA therapy alone. This case illustrates the potential for successful use of GLP-1 RA monotherapy in patients with HNF1A MODY. Endocrine Society 2019-10-03 /pmc/articles/PMC6846329/ /pubmed/31737858 http://dx.doi.org/10.1210/js.2019-00278 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Fantasia, Kathryn L
Steenkamp, Devin W
Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
title Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
title_full Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
title_fullStr Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
title_full_unstemmed Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
title_short Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
title_sort optimal glycemic control in a patient with hnf1a mody with glp-1 ra monotherapy: implications for future therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6846329/
https://www.ncbi.nlm.nih.gov/pubmed/31737858
http://dx.doi.org/10.1210/js.2019-00278
work_keys_str_mv AT fantasiakathrynl optimalglycemiccontrolinapatientwithhnf1amodywithglp1ramonotherapyimplicationsforfuturetherapy
AT steenkampdevinw optimalglycemiccontrolinapatientwithhnf1amodywithglp1ramonotherapyimplicationsforfuturetherapy

Ejemplares similares